Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2
ACCRU-GI-2017
A Phase II Study of Nivolumab + Ipilimumab in Advanced HCC Patients Who Have Progressed on First Line Atezolizumab + Bevacizumab
- NCT05199285 ↗
- Terminated
- Academic and Community Cancer Research United
- Focused size, estimated: 1–150 verified statements
We haven't built an HCP commentary report on ACCRU-GI-2017 yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on ACCRU-GI-2017 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 5 posts on X | |
| 1 YouTube video |
The trial
ClinicalTrials.gov- Official title
- A Phase II Study of Nivolumab + Ipilimumab in Advanced HCC Patients Who Have Progressed on First Line Atezolizumab + Bevacizumab
- Phase
- Phase 2
- Status
- Terminated
- Conditions
- BCLC Stage B Hepatocellular Carcinoma; BCLC Stage C Hepatocellular Carcinoma; Locally Advanced Hepatocellular Carcinoma; Metastatic Hepatocellular Carcinoma; Stage III Hepatocellular Carcinoma AJCC v8; Stage IIIA Hepatocellular Carcinoma AJCC v8; Stage IIIB Hepatocellular Carcinoma AJCC v8; Stage IV Hepatocellular Carcinoma AJCC v8; Stage IVA Hepatocellular Carcinoma AJCC v8; Stage IVB Hepatocellular Carcinoma AJCC v8; Unresectable Hepatocellular Carcinoma
- Interventions
- Ipilimumab; Nivolumab
- Arms
- Treatment (nivolumab, ipilimumab) · Experimental
- Enrollment
- 15
- Primary outcomes
- Confirmed objective response rate (ORR)
- Sponsor
- Academic and Community Cancer Research United with National Cancer Institute (NCI)
- Start
- Jan 19, 2023
- Primary completion
- Feb 1, 2026
- Results posted
- No
- Registry record
- NCT05199285 · updated Aug 4, 2026